Longevity research consistently identifies cardiovascular disease, metabolic dysfunction, and systemic inflammation as the dominant drivers of premature death worldwide. Large epidemiological analyses confirm that vascular disease remains the leading cause of years of life lost across virtually every region of the world [1]. Against this backdrop, scientists and consumers have grown interested in dietary and supplemental strategies that may support vascular health: among them nattokinase, an enzyme extracted from natto, a traditional Japanese fermented soybean food.
Nattokinase is a serine protease produced by Bacillus subtilis during the fermentation that transforms soybeans into natto. Unlike many supplement ingredients studied primarily in cell culture, nattokinase has demonstrated measurable fibrinolytic activity in human plasma studies, and small randomized trials have reported modest blood pressure changes, although a 3-year trial in 265 healthy adults found no effect on blood pressure [6][7][8]. This article examines what population-level evidence says about cardiovascular aging, what the trial data on nattokinase actually shows, and where the honest scientific limits currently lie.
Key Takeaways
- Cardiovascular disease remains the leading driver of premature death globally, making vascular health central to any evidence-based longevity discussion [1].
- Nattokinase is a fibrinolytic serine protease that degrades fibrin directly and in lab and animal work appears to raise tissue plasminogen activator activity [9][10][11], with measurable activity confirmed in human plasma studies.
- Small trials report modest blood pressure changes and an uncontrolled study reported lower fibrinogen, but the longest placebo-controlled trial (265 healthy adults, median 3 years) found no effect on blood pressure, artery thickening or laboratory measures, and no trial has established effects on hard cardiovascular outcomes or lifespan [6][12][8].
- Nattokinase must not be combined with anticoagulants or antiplatelet drugs without physician supervision and should be discontinued at least one week before any surgical procedure.
- Longevity patterns in populations that eat natto cannot be attributed to nattokinase alone: overall dietary pattern, metabolic health, and lifestyle factors are dominant determinants of lifespan [2].
Cardiovascular Disease, Aging, and the Longevity Gap
The relationship between heart disease and lifespan is not subtle. A comprehensive analysis of mortality across 204 countries from 1990 to 2021 found that cardiovascular diseases consistently account for the largest share of global mortality, with ischemic heart disease and stroke driving the majority of life-years lost [3]. A separate analysis of global mortality trends found that while life expectancy has increased substantially over the past seven decades, much of the remaining gap between current and theoretical maximum healthy lifespan is attributable to circulatory and metabolic disease [4].
Cardiovascular risk is not static across adulthood. Atherosclerosis progresses over decades, fibrin accumulation contributes to thrombotic risk, and the balance between procoagulant and fibrinolytic activity in the blood tends to shift unfavorably with age. This biological context is part of why researchers have examined whether dietary components or supplements with fibrinolytic properties might influence vascular aging, even though direct longevity endpoints have not been established in controlled trials of nattokinase.
What Nattokinase Is and How It Works
Nattokinase is a serine protease, meaning it cleaves proteins through a serine-containing catalytic site, secreted by Bacillus subtilis during natto fermentation. Its primary characterized action is direct enzymatic degradation of fibrin, the protein scaffold of blood clots. In lab and animal studies it also appears to raise tissue plasminogen activator (tPA) activity, but a 3-year trial in 265 healthy adults found no effect on tPA antigen [9][10][11][8].
Fibrinolytic units (FU) are the standard measure of nattokinase potency, and most commercially available supplements are standardized to 2,000 to 4,000 FU per serving. A review reports intact nattokinase in the serum of healthy people after a single 2,000 FU capsule, but EFSA said the supplied data could not show whether active nattokinase is absorbed [13][12]. Small randomized trials have reported modest blood pressure changes (one found only a diastolic fall and the longest found none), and an uncontrolled study found that fibrinogen, factor VII and factor VIII fell after two months [6][7][8][12]both markers associated with clotting tendency.
Antiplatelet activity has been documented in rabbit and rat plasma tests rather than in human trials, meaning nattokinase may reduce platelet aggregation in addition to its fibrinolytic effects [14][15]. This dual mechanism, fibrinolytic and antiplatelet, is clinically significant because it may increase the potential for bleeding interactions with anticoagulant and antiplatelet medications (human interaction data are lacking) [16][17], a safety consideration that must not be minimized.
Natto as a Traditional Food and Its Place in Japanese Dietary Patterns
Natto itself is not simply a delivery vehicle for nattokinase. It is a nutritionally dense food containing high levels of vitamin K2 (specifically menaquinone-7, or MK-7), plant protein, dietary fiber, and a range of B vitamins. Vitamin K2 has been associated in observational research with improved arterial calcium metabolism and reduced arterial stiffness, making it difficult to isolate nattokinase’s effects from those of the broader food matrix when studying natto consumers.
Japan, where natto is consumed regularly by a significant portion of the population, has among the longest life expectancies in the world. However, attributing this longevity advantage to natto specifically is epidemiologically unsound. Japanese dietary patterns differ from Western patterns in dozens of ways simultaneously, including lower saturated fat intake, higher fish consumption, lower caloric density, and different carbohydrate quality. Cardiovascular disease burden is shaped by a large number of lifestyle, genetic, and environmental factors [1], and although a Japanese cohort linked higher natto intake to lower mortality, that is an observational association and does not show that natto itself is the cause [18].
Observational data do link whole natto food to lower mortality. In a Japanese cohort summarized in a 2025 systematic review, higher natto intake was associated with lower all-cause mortality in women (HR 0.84) and lower cardiovascular mortality in men (HR 0.76) and women (HR 0.79). This concerns the whole food, not nattokinase supplements, and an association does not prove cause [18].
What Small Human Trials Actually Show
The human clinical evidence on nattokinase supplements is limited and mixed. Most trials have been small and short, but one double-blind trial followed 265 healthy adults for a median of 3 years and found no effect on carotid artery thickening, blood pressure or any laboratory measure [8]. Trials to date have generally been small, fewer than 100 participants, short in duration (typically 8 to 26 weeks), and have used surrogate markers such as fibrinogen, blood pressure, and carotid intima-media thickness rather than hard clinical endpoints like myocardial infarction, stroke, or all-cause mortality. No large long-term randomized controlled trial has established whether nattokinase supplementation reduces cardiovascular events or extends lifespan.
Blood pressure findings are mixed. A 2008 maker-funded trial in 86 adults reported 5.55 mmHg lower systolic and 2.84 mmHg lower diastolic pressure than placebo, a 2016 trial in 79 adults found only the diastolic reading fell, a 2023 meta-analysis of a few small trials pooled to 3.45 and 2.32 mmHg, and a 3-year trial in 265 healthy adults found no effect [6][7][11][8]. While modest, even small sustained blood pressure reductions are associated with meaningful population-level reductions in stroke and coronary events: a relationship well-established in antihypertensive research. Whether nattokinase produces these benefits durably and across diverse patient populations remains unresolved.
Fibrinogen reduction has been reported in an uncontrolled study of 15 healthy volunteers, which cannot show that nattokinase caused it [12]. Fibrinogen is a direct precursor to fibrin and an independent risk factor for cardiovascular events at elevated levels. Observed reductions in small trials are encouraging but must be interpreted cautiously given study size and duration limitations.
Metabolic Disease, Aging, and What Population Data Implies for Context
Longevity is not determined by any single biochemical pathway. A large meta-analysis of cohorts totaling over 100,000 participants found that dietary glycemic load was independently associated with increased risk of type 2 diabetes, cardiovascular disease, and all-cause mortality [2]. This underscores a key principle relevant to nattokinase research: vascular aging is a multifactorial process in which diet quality, metabolic health, inflammation, and fibrinolytic balance interact continuously. No supplement operates in isolation from these broader determinants.
Chronic kidney disease, which substantially accelerates cardiovascular risk and is itself a major contributor to global disease burden in aging populations [5], is associated with altered coagulation dynamics and fibrin accumulation. This has led some researchers to consider fibrinolytic agents in this context, though no large, well-replicated nattokinase trial in CKD populations exists. Supplement use in CKD requires physician oversight given altered drug metabolism and heightened bleeding risk.
Safety, Drug Interactions, and the Limits of Current Evidence
Nattokinase’s fibrinolytic and antiplatelet activity is a meaningful biological signal, and a meaningful safety consideration. It must not be combined with anticoagulants (warfarin, heparin, direct oral anticoagulants such as apixaban or rivaroxaban) or antiplatelet agents (aspirin, clopidogrel, ticagrelor) without direct physician supervision. The combination may increase bleeding risk; human interaction data are lacking, and a Health Canada licence says not to use it with products that affect blood coagulation [16][19]. Nattokinase should be discontinued at least one week before any elective surgical procedure.
The FDA has not evaluated nattokinase for treating, curing, or preventing any disease. Most supportive human trials are small and short-term, meaning that long-term safety data are limited. Because natto, the whole food, contains vitamin K2, which interacts with warfarin’s mechanism of action, individuals on warfarin anticoagulation should exercise caution with both natto consumption and nattokinase supplementation and discuss this with their prescribing physician. Individuals with bleeding disorders, those recovering from recent surgery, pregnant or breastfeeding women, and anyone managing a chronic cardiovascular or renal condition should consult a qualified healthcare provider before use.
ð Where to Buy Nattokinase
- Doctor’s Best Nattokinase 2,000 FU
capsules, 100 mg NSK-SD per vcap (2,000 FU): Nattokinase from an established supplement brand; vegetarian capsules; 90 count - NOW Foods Nattokinase 100 mg
capsules, 100 mg per vcap (2,000 FU): Mainstream brand with third-party GMP-certified manufacturing; affordable entry-level option; 90 vcaps; widely available - Source Naturals Nattokinase 100 mg
capsules, 100 mg per tablet (2,000 FU): Long-established supplement brand; competitive pricing at 60 tablets; good for budget-conscious buyers familiar with the brand - Healthy Origins Nattokinase 2,000 FU
capsules, 100 mg per vcap (2,000 FU): Best cost-per-serving option on Amazon; 180 vcap bottle; uses NSK-SD ingredient; popular bulk buy for long-term users
As an Amazon Associate we earn from qualifying purchases. Nattokinase is sold on an enzymatic activity claim, and independent testing has repeatedly found bottles delivering well under their labelled potency. Check that the label states fibrinolytic units (FU) per capsule rather than milligrams alone, and prefer a brand that will supply a batch-specific certificate of analysis showing the measured FU result for that lot, since GMP certification alone does not verify it.
A Note on the Evidence
The human trial evidence for nattokinase is preliminary: most studies are small, short-term, and rely on surrogate markers rather than clinical endpoints, so no conclusions about cardiovascular events or longevity can yet be drawn. Nattokinase has genuine fibrinolytic and antiplatelet activity that creates real bleeding risk when combined with anticoagulant or antiplatelet medications; anyone on blood-thinning drugs, managing a chronic health condition, or approaching surgery should consult a physician before use. This article is informational only and does not constitute medical advice.
Frequently Asked Questions
Does nattokinase extend human lifespan?
No study has demonstrated that nattokinase supplementation extends human lifespan. Population studies confirm that cardiovascular disease is a leading driver of premature death globally [3], and nattokinase has been studied for surrogate cardiovascular markers, but hard longevity endpoints have not been tested in large controlled trials. Claims linking nattokinase to extended lifespan are not supported by available evidence.
What does nattokinase actually do in the body?
Nattokinase is a serine protease that directly degrades fibrin, the structural scaffold of blood clots, and in lab and animal work appears to raise tissue plasminogen activator activity. Small trials have reported modest blood pressure changes, and an uncontrolled study reported lower fibrinogen [9][10][12][6]. It also has antiplatelet activity, which is relevant to both its potential cardiovascular effects and its interaction risks with blood-thinning medications.
Is eating natto the same as taking a nattokinase supplement?
Not exactly. Natto provides nattokinase alongside vitamin K2 (MK-7), plant protein, fiber, and B vitamins. Supplements isolate and standardize the enzyme by fibrinolytic units. These two forms may have different effects given natto’s nutritional complexity, and the vitamin K2 content of natto is itself an important variable, particularly for anyone taking warfarin, where K2 directly affects anticoagulation status.
Why do Japanese populations live longer: is it because they eat natto?
Japan has among the world’s highest life expectancies, but this cannot be validly attributed to natto. Japanese dietary patterns differ from Western diets in numerous ways simultaneously, and cardiovascular and metabolic disease burden reflects many interacting lifestyle, genetic, and environmental factors [1]. A large meta-analysis of over 100,000 participants also highlights that overall dietary quality, including glycemic load, is independently associated with mortality risk [2], reinforcing that no single food drives population-level longevity.
Who should not take nattokinase?
Anyone taking anticoagulants (warfarin, heparin, apixaban, rivaroxaban) or antiplatelet agents (aspirin, clopidogrel, ticagrelor) should not take nattokinase without physician supervision due to combined bleeding risk. Those with bleeding disorders, chronic kidney disease [5], upcoming surgery, pregnancy, or breastfeeding should also consult a doctor before use. Nattokinase should be stopped at least one week before any planned surgical procedure.
How strong is the evidence for nattokinase's cardiovascular benefits?
The human evidence consists primarily of small randomized controlled trials lasting 8 to 26 weeks that measure surrogate markers: blood pressure, fibrinogen, carotid intima-media thickness, rather than clinical outcomes such as stroke or heart attack. Results are mixed: some small trials reported modest blood pressure reductions, while the longest trial (265 healthy adults, median 3 years) found none, and the trials are too small and short to establish effects on cardiovascular events or mortality [6][7][8]. The FDA has not approved nattokinase for treating or preventing any disease, and the evidence base should be considered preliminary.
References
- Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators et al. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. Journal of the American College of Cardiology (2025). PMID 40990886
- Jenkins DJA et al. Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100â000 participants. The lancet. Diabetes & endocrinology (2024). PMID 38272606
- GBD 2021 Causes of Death Collaborators et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet (London, England) (2024). PMID 38582094
- GBD 2021 Demographics Collaborators et al. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet (London, England) (2024). PMID 38484753
- GBD 2023 Chronic Kidney Disease Collaborators et al. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet (London, England) (2025). PMID 41213283
- Kim JY et al. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertension research : official journal of the Japanese Society of Hypertension (2008). PMID 18971533
- Jensen GS et al. Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integrated blood pressure control (2016). PMID 27785095
- Hodis HN et al. Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clinical hemorheology and microcirculation (2021). PMID 33843667
- Tetsumei Urano et al. The Profibrinolytic Enzyme Subtilisin NAT Purified fromBacillus subtilis Cleaves and Inactivates Plasminogen Activator Inhibitor Type 1. Journal of Biological Chemistry (2001). PMID 11325965
- Hiroyuki Sumi et al. Natto Bacillus as an Oral Fibrinolytic Agent: Nattokinase Activity and the Ingestion Effect of Bacillus subtilis natto. Food Science and Technology Research (2004). doi:10.3136/fstr.10.17
- Li X et al. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in cardiovascular medicine (2023). PMID 39076715
- European Food Safety Authority (EFSA NDA Panel) Safety of fermented soybean extract NSK-SD as a novel food pursuant to Regulation (EC) No 258/97. European Food Safety Authority (EFSA NDA Panel) (2016). source
- Weng Y et al. Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardiovascular Disease. International journal of molecular sciences (2017). PMID 28264497
- JaâYoung Jang et al. Nattokinase improves blood flow by inhibiting platelet aggregation and thrombus formation. Laboratory Animal Research (2013). PMID 24396387
- Jae-Bum Kim et al. Evaluation of Nattokinase for Antithrombotic Effect and Pharmacological Efficacy by a Biological Test and Clinical Trial. KSBB Journal (2011). doi:10.7841/ksbbj.2011.26.5.393
- Chen H et al. Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases. Biomarker insights (2018). PMID 30013308
- Muric M et al. Comparative Cardioprotective Effectiveness: NOACs vs. Nattokinase-Bridging Basic Research to Clinical Findings. Biomolecules (2024). PMID 39199344
- Paveljšek D et al. A systematic review of prospective evidence linking non-alcoholic fermented food consumption with lower mortality risk. Frontiers in nutrition (2025). PMID 41256929
- Health Canada Licensed Natural Health Product NPN 80089299: Nattokinase 100 mg. Health Canada (2026). source
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
